Torsten Therapeutics

Torsten Therapeutics is a biotechnology company focused on developing novel therapies for neurodegenerative and neuropsychiatric disorders by targeting the brain's innate immune system. Founded and incubated by Apple Tree Partners (ATP), the company leverages a proprietary platform to identify small molecules that modulate microglial function to restore neuronal health and homeostasis. Their approach addresses the underlying neuroinflammation and cellular dysfunction that drive the progression of diseases such as Alzheimer's and frontotemporal dementia. By re-engineering the brain's immune response, Torsten aims to provide transformative treatments for conditions with high unmet medical needs. The company is currently advancing multiple programs through discovery and pre-clinical development.